Stock Events

Biomind Labs 

C$0.68
2
+C$0+0% Tuesday 13:40

Statistics

Day High
0.68
Day Low
0.68
52W High
1.09
52W Low
0.03
Volume
1,100
Avg. Volume
1,178
Mkt Cap
50.84M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Dividends

0%Dividend Yield
Nov 20
C$0.02
Dec 19
C$0.1
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BMND.NEO. It's not an investment recommendation.
Alphabet
68918
GOOGL
Apple
60554
AAPL
Microsoft
56693
MSFT
Amazon
51850
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Compass Pathways
CMPS
Mkt Cap499.18M
Compass Pathways operates in the psychedelic medicine sector, focusing on psilocybin therapy for depression, similar to Biomind's work on psychedelic-based treatments.
Mind Medicine
MNMD
Mkt Cap49.83M
Mind Medicine works on developing psychedelic-inspired therapies, directly competing with Biomind Labs in the neuropharmaceutical space.
ATAI Life Sciences N.V.
ATAI
Mkt Cap247.76M
ATAI Life Sciences is a biotech company researching and developing treatments using psychedelics, overlapping with Biomind Labs' focus areas.
GH Research
GHRS
Mkt Cap574.91M
GH Research focuses on developing 5-MeO-DMT therapies for depression, a direct competitor in the psychedelic treatment market.
Cybin
CYBN
Mkt Cap223.09M
Cybin Inc. develops psychedelic compounds for therapy, which competes with Biomind Labs' similar approach in mental health treatments.
Revive Therapeutics
RVVTF
Mkt Cap3.77M
Revive Therapeutics explores psychedelic medicines for various disorders, positioning it as a competitor in the psychedelic drug development industry.
Mydecine Innovations
MYCOF
Mkt Cap561,974
Mydecine Innovations Group works on developing and commercializing psychedelic medicines, competing in the same therapeutic space as Biomind Labs.

About

Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; and BMND08, a 5-Methoxy-N,N-dimethyltryptamine based candidate that is in Phase II clinical trials for treatment of depression and anxiety in patients with Alzheimer's-type cognitive impairment. It is also developing new and preclinical drug candidates, including BMND02 for treating fibromyalgia, BMND03 for treating addictive disorders, BMND05 for treating chronic pain, BMND06 for treating inflammatory disorders, and BMND07 for treating major depressive disorder. The company is headquartered in Canelones, Uruguay.
Show more...
CEO
Mr. Alejandro Antalich
Employees
5
Country
CA
ISIN
CA0907021012
WKN
000A3CSQR

Listings

NEO
CA
BMND.NEO
OTCM
US
BMNDF
F
DE
3XI.F